Who
Corwin Dale Hooks
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Spruce Biosciences; Chief Commercial Officer, Applied Therapeutics; Officer, Clovis Oncology.
In numbers
- Trades disclosed
- 46
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $207K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 1 Feb 2016
- Last trade
- 9 Mar 2026
- Last filed
- 9 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Mar 2026filed 9 Mar 2026 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 9 Mar 2026filed 9 Mar 2026 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied TherapeuticsBiotechnology | SEC FORM 4 Code D | —862,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied TherapeuticsBiotechnology | SEC FORM 4 Code U | —5,753 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeutics | SEC FORM 4 Code D | —862,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeutics | SEC FORM 4 Code U | —5,753 | filing |
| 19 Dec 2025filed 3 Feb 2026 | Applied TherapeuticsBiotechnology | SEC FORM 4 Code A | —312,500 at $0.00 | filing |
| 19 Dec 2025filed 3 Feb 2026 | Applied Therapeutics | SEC FORM 4 Code A | —312,500 at $0.00 | filing |
| 24 Mar 2025filed 26 Mar 2025 | Applied Therapeutics | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 12 Apr 2024filed 15 Apr 2024 | Applied Therapeutics | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 5 Sep 2018filed 7 Sep 2018 | Clovis Oncologyoption or derivative | SEC FORM 4 Code M | —469 at $0.00 | filing |
| 5 Sep 2018filed 7 Sep 2018 | Clovis Oncology | SEC FORM 4 Code M | —469 | filing |
| 5 Sep 2018filed 7 Sep 2018 | Clovis Oncology | SEC FORM 4 Code F | $8,544239 at $35.75 | filing |
| 27 Aug 2018filed 28 Aug 2018 | Clovis Oncology | SEC FORM 4 Code M | —869 | filing |
| 27 Aug 2018filed 28 Aug 2018 | Clovis Oncology | SEC FORM 4 Code F | $15K434 at $35.15 | filing |
| 27 Aug 2018filed 28 Aug 2018 | Clovis Oncologyoption or derivative | SEC FORM 4 Code M | —869 at $0.00 | filing |
| 15 Jun 2018filed 27 Dec 2018 | Clovis Oncology | SEC FORM 4 Sold | $43K939 at $45.47 | filing |
| 6 Jun 2018filed 8 Jun 2018 | Clovis Oncology | SEC FORM 4 Code M | —468 | filing |
| 6 Jun 2018filed 8 Jun 2018 | Clovis Oncology | SEC FORM 4 Code F | $11K235 at $47.70 | filing |
| 6 Jun 2018filed 8 Jun 2018 | Clovis Oncologyoption or derivative | SEC FORM 4 Code M | —468 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.